Mycosis Fungoides
Conditions
Brief summary
Tissue and serum samples from 20 MF patients and 20 normal healthy controls will be subjected for biochemical assessments by ELISA (Enzyme- linked immune-sorbent assay) for assessing the level of IL35.
Detailed description
Tissue and serum samples from 20 MF patients and 20 normal healthy controls will be subjected for biochemical assessments by ELISA (Enzyme- linked immune-sorbent assay) for assessing the level of IL35
Interventions
DIAGNOSTIC_TESTSkin biopsy
biochemical assessment for measurement IL35 by ELISA (Enzyme linked immunosorbent assay) technique in tissue and serum samples of all thirty patients and healthy controls.
Sponsors
Cairo University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients with mycosis fungoides. Both genders. Age group ≥ 18 years old.
Exclusion criteria
* Patients with any other skin diseases. Patients who received treatments for mycosis fungoides in the past three months. Subjects with history of solid or hematological malignancy as leukemia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To assess and compare tissue and serum levels of interleukin 35 (IL -35) in mycosis fungoides patients and normal controls. | 1 year | To assess and compare tissue and serum levels of interleukin 35 (IL -35) in mycosis fungoides patients and normal controls. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlating tissue and serum levels of IL-35 in mycosis fungoides patients with patients age, sex, duration, extent and stage of the disease. L | 1 year | Correlating tissue and serum levels of IL-35 in mycosis fungoides patients with patients age, sex, duration, extent and stage of the disease. |
Countries
Egypt
Contacts
Primary ContactSally Doss, MD
Outcome results
None listed